Trial · NCT00241631

Enhancement of in-Vitro GC Function in Patients With COPD

NCT00241631, Phase 2, Completed, Imperial College London; results first posted 2019-12-04

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Enhancement of in-Vitro GC Function in Patients With COPD. Trials, record NCT00241631. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00241631

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Enhancement of in-Vitro GC Function in Patients With COPD
NCT number: NCT00241631
Status: Completed
Phases: Phase 2
Enrollment: 49 participants, actual
Lead sponsor: Imperial College London
Conditions: COPD
Interventions: Fluticasone Propionate, placebo, Theophylline
First posted: 2005-10-19
Last updated: 2019-12-04
Results first posted: 2019-12-04

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Sputum Inflammatory Cell Counts	10 weeks	Supernatant collect, cell pellets count on slides
Secondary	Interleukin 8 (IL8)	10 weeks	Interleukin 8 (IL8) assessed from sputum
Secondary	Total Sputum Eosinophils	10 weeks	Total eosinophils cells assessed from sputum

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Sputum Inflammatory Cell Counts	10 weeks	Using marginal means as results	millions cells/ ml	MEAN
SECONDARY	Interleukin 8 (IL8)	10 weeks		ng/mL	MEAN
SECONDARY	Total Sputum Eosinophils	10 weeks		millions cells/ml	MEAN

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Sputum Inflammatory Cell Counts	Placebo	5.42	95% Confidence Interval 3.56 to 8.2	millions cells/ ml
Sputum Inflammatory Cell Counts	Steroid	3.89	95% Confidence Interval 2.6 to 5.76	millions cells/ ml
Interleukin 8 (IL8)	Placebo	33.3	95% Confidence Interval 20 to 56	ng/mL
Interleukin 8 (IL8)	Steroid	28.3	95% Confidence Interval 19 to 42	ng/mL
Total Sputum Eosinophils	Placebo	0.132	95% Confidence Interval 0.09 to 0.2	millions cells/ml
Total Sputum Eosinophils	Steroid	0.053	95% Confidence Interval 0.03 to 0.1	millions cells/ml

Source ClinicalTrials.gov

Participant flow24

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Run in (2 Weeks)	STARTED	Placebo	25
Run in (2 Weeks)	STARTED	Steroid	24
Run in (2 Weeks)	COMPLETED	Placebo	22
Run in (2 Weeks)	COMPLETED	Steroid	21
Run in (2 Weeks)	NOT COMPLETED	Placebo	3
Run in (2 Weeks)	NOT COMPLETED	Steroid	3
Phase 1 (4 Weeks)	STARTED	Placebo	22
Phase 1 (4 Weeks)	STARTED	Steroid	21
Phase 1 (4 Weeks)	COMPLETED	Placebo	14
Phase 1 (4 Weeks)	COMPLETED	Steroid	16

1 to 10 of 24Source ClinicalTrials.gov

See all 24 participant flow

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Nausea	Gastrointestinal disorders	Placebo	0	14	0
other	Nausea	Gastrointestinal disorders	Steroid	4	16	4

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo	0	14
Total, all-cause mortality	Steroid	0	16
Total, other adverse events	Placebo	0	14
Total, other adverse events	Steroid	4	16
Total, serious adverse events	Placebo	0	14
Total, serious adverse events	Steroid	0	16

Source ClinicalTrials.gov

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
15888697	BACKGROUND	PubMed
20299628	RESULT	PubMed
24525446	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Steroid vs Placebo: deaths from any cause	Trial comparisons
Steroid vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00241631

GET https://conductscience.org/api/trials/v1/NCT00241631/flow?page=2

API reference For AI assistants